Cargando…

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

BACKGROUND: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiaohui, Bao, Zhengqiang, Zhang, Xiaoju, Li, Fei, Lai, Tianwen, Cao, Chao, Chen, Zhihua, Li, Wen, Shen, Huahao, Ying, Songmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601788/ https://www.ncbi.nlm.nih.gov/pubmed/28938692 http://dx.doi.org/10.18632/oncotarget.18316

Ejemplares similares

The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis
por: Zhang, Hao, et al.
Publicado: (2017)

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis
por: Bao, Zhengqiang, et al.
Publicado: (2015)

IL-17-Mediated Inflammation Promotes Cigarette Smoke-Induced Genomic Instability
por: Cao, Chao, et al.
Publicado: (2021)

Unrepaired DNA damage in macrophages causes elevation of particulate matter- induced airway inflammatory response
por: Luo, Man, et al.
Publicado: (2018)

Efficacy and safety of combination PD‐1/PD‐L1 checkpoint inhibitors for malignant solid tumours: A systematic review
por: Yao, Qigu, et al.
Publicado: (2020)

Oleandrin induces DNA damage responses in cancer cells by suppressing the expression of Rad51
por: Bao, Zhengqiang, et al.
Publicado: (2016)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023)

The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
por: Nie, Run-Cong, et al.
Publicado: (2020)

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

Corrigendum: Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis
por: Lai, Tianwen, et al.
Publicado: (2015)

Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
por: Guo, Xiaodi, et al.
Publicado: (2020)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Wang, Miao, et al.
Publicado: (2021)

Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer
por: Mo, Dun-Chang, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis
por: Cao, Chao, et al.
Publicado: (2016)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis
por: Wang, Bi‐Cheng, et al.
Publicado: (2019)

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies
por: Tang, Hui, et al.
Publicado: (2022)

Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment
por: Su, Qiang, et al.
Publicado: (2018)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis
por: Huang, Qingyuan, et al.
Publicado: (2021)

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies
por: Sakakida, Tomoki, et al.
Publicado: (2020)

Molecular characterization of clinical responses to PD‐1/PD‐L1 inhibitors in non‐small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD‐1 inhibitors in Chinese patients
por: Song, Peng, et al.
Publicado: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
por: Jelinek, Tomas, et al.
Publicado: (2018)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
por: Al-Showbaki, Laith, et al.
Publicado: (2021)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
por: Abdin, Shifaa M., et al.
Publicado: (2018)

The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis
por: Si, Zhihua, et al.
Publicado: (2019)

Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
por: Weng, Yi Ming, et al.
Publicado: (2018)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dd3vpputgl142234mu05ghcelf